ContraFect Announces Presentation of New Data from its Amurin Peptide Program at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance August 28, 2019
ContraFect Announces ASM Microbe 2019 Outstanding Abstract Award and Presentation of New Data June 17, 2019
ContraFect Awarded $7.2 Million USAMRDC Grant to Support the Advancement of Lysin Candidate CF-296 June 6, 2019
ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium June 3, 2019
ContraFect Announces Publication of Paper on Recent Exebacase Data in Antimicrobial Agents and Chemotherapy Journal May 31, 2019
ContraFect to Host R&D Symposium on Direct Lytic Agents (Lysins and Amurins) with Clinical Thought Leaders on Infectious Disease May 8, 2019
ContraFect Presents Additional Positive Data from the Phase 2 Trial of Exebacase at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) April 16, 2019
ContraFect Announces Publication of Exebacase Data in Antimicrobial Agents and Chemotherapy Journal April 8, 2019
